Hot News

《大行報告》美銀美林:中生制藥(01177.HK)事件引發行業系統性風險降級至「跑輸大市」 @ 2013-09-13T14: Back Hot News
Keyword:中生制藥 賄賂
Concept:中生制藥停牌 , 涉賄賂中國生物制藥
被指旗下涉賄賂 中生制藥急挫後突停牌
中國生物制藥(01177)被指涉嫌商業賄賂,股價今早大幅低開15.8%,報4.8元,之後曾大跌24.9%,低見4.28元。股份盤前錄得335.2萬股成交上板,每股作價4.8元,涉資1609萬元。最新股價挫14%報4.9元。德銀認為中生制藥短期會有陣痛,惟長線則看好,維持「買入」評級。
據信報報道,中國生物制藥(01177)旗下一家合資藥廠,被指涉嫌商業賄賂,中生制藥盤前錄得一筆共335.2萬股成交上板,每股作價4.8元,涉資約1609萬元,今早暫低見4.28元,現報4.71元,急瀉17.37%,成交4.95億元,暫居成交榜首。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.